PeptideJournal
Reference16 min read

How Peptides Work: Mechanisms of Action Explained

You know that peptides are short chains of amino acids. You may know that [semaglutide](/peptides/semaglutide-complete-pharmacology-guide/) helps with weight loss and [BPC-157](/peptides/bpc-157-complete-scientific-guide/) is studied for tissue repair.

You know that peptides are short chains of amino acids. You may know that semaglutide helps with weight loss and BPC-157 is studied for tissue repair. But how do these molecules actually produce their effects? What happens at the cellular level when a peptide enters your body?

This article walks through the machinery of peptide action — from the moment a peptide binds its receptor to the cascade of events inside the cell that produces the final biological response. Understanding these mechanisms won't just satisfy your curiosity. It will give you the framework to evaluate peptide claims, understand why certain peptides need injection while others work topically, and make sense of the scientific literature.

Table of Contents

The Big Picture: Peptides as Messengers

Peptides are signaling molecules. They carry information from one cell to another, telling the receiving cell to do something specific — release a hormone, produce a protein, divide, migrate, or die.

This is fundamentally different from how most small-molecule drugs work. A typical drug like aspirin or ibuprofen enters cells and directly blocks an enzyme. Peptides, by contrast, usually don't enter cells at all. They work from the outside, binding to receptors on the cell surface and triggering a cascade of events inside.

The process happens in five steps:

  1. Receptor binding — The peptide locks onto a specific receptor on the cell surface.
  2. Signal transduction — The receptor changes shape and activates intracellular signaling proteins.
  3. Second messenger production — Small molecules amplify and relay the signal throughout the cell.
  4. Cellular response — The cell changes its behavior (gene expression, enzyme activity, secretion, etc.).
  5. Signal termination — The system shuts itself off to prevent overstimulation.

Each step matters. And each step is a potential point of therapeutic intervention — which is why understanding these mechanisms is relevant to understanding how peptide drugs work.

Step 1: Receptor Binding — The Lock and Key

When a peptide circulates through the blood or is injected into tissue, it eventually encounters cells that display the right receptor on their surface. The peptide binds to this receptor with high specificity — its amino acid sequence and three-dimensional shape must match the receptor's binding site. If the fit is wrong, nothing happens. This specificity is what allows peptides to target particular cells and tissues while leaving others alone.

Types of Peptide Receptors

Most peptide receptors fall into three major categories:

G Protein-Coupled Receptors (GPCRs) — The dominant receptor type for peptides. GPCRs are a massive family of about 800 different receptors in the human genome, representing roughly 80% of all known receptors. They share a common architecture: a single protein chain that snakes back and forth across the cell membrane seven times, creating seven transmembrane helices.

Peptide hormones and neuropeptides overwhelmingly target GPCRs. The GLP-1 receptor (target of semaglutide and liraglutide), the ghrelin receptor (target of ipamorelin and GHRP-6), opioid receptors (target of endorphins), and oxytocin receptors are all GPCRs.

The peptide-binding site on these receptors involves residues in both the large extracellular N-terminal domain and the transmembrane domain. These multiple contact points give neuropeptide receptors remarkably high affinity for their ligands — typically binding in the nanomolar concentration range. That means incredibly small amounts of peptide can produce a response.

Receptor Tyrosine Kinases (RTKs) — Single-pass transmembrane receptors with built-in enzyme activity. When a growth factor peptide (like EGF, insulin, or IGF-1) binds, the receptor's intracellular domain activates its kinase function, phosphorylating itself and downstream targets. The insulin receptor and IGF-1 receptor are both RTKs.

RTKs work differently from GPCRs. Instead of activating G proteins, they directly phosphorylate (add phosphate groups to) intracellular proteins, initiating cascades like the PI3K/Akt and Ras/MAPK pathways. These pathways regulate cell growth, differentiation, and survival.

Ion Channel Receptors — Some peptides directly open or close ion channels in the cell membrane, allowing charged particles (ions) to flow in or out. This is particularly relevant for neuropeptides in the nervous system, where rapid ion flux drives electrical signaling.

Step 2: Signal Transduction — Relaying the Message

Once a peptide binds its receptor, the receptor's shape changes. This conformational change is the triggering event that converts an extracellular signal into an intracellular one.

GPCR Signaling: The G Protein Relay

For GPCRs, the conformational change activates a G protein sitting on the inside of the cell membrane. G proteins work like molecular switches:

  • Off state: The G protein has three subunits (alpha, beta, gamma). The alpha subunit holds GDP (guanosine diphosphate) and sits idle.
  • Activation: The receptor acts as a guanine nucleotide exchange factor (GEF) — it causes the alpha subunit to release GDP and grab GTP (guanosine triphosphate) instead.
  • Signal relay: The GTP-bound alpha subunit separates from the beta-gamma dimer. Both pieces can now interact with downstream effector enzymes.

The type of alpha subunit determines what happens next:

G Protein TypeEffectDownstream Target
GαsStimulatoryActivates adenylyl cyclase → increases cAMP
Gαi/oInhibitoryInhibits adenylyl cyclase → decreases cAMP
Gαq/11Phospholipase C pathwayActivates PLC → produces IP3 and DAG
Gα12/13Cytoskeletal regulationActivates Rho GTPases

This is why the same peptide can produce different effects in different tissues. The response depends not just on which receptor the peptide binds, but on which G proteins and downstream effectors are present in that particular cell type.

RTK Signaling: Direct Phosphorylation

For receptor tyrosine kinases, the mechanism is more direct. Growth factor binding causes two receptor molecules to pair up (dimerize) and phosphorylate each other's intracellular domains. These phosphorylated sites then serve as docking stations for signaling proteins that contain specific recognition domains.

The key downstream cascades include:

  • Ras/MAPK pathway: Drives cell proliferation and differentiation
  • PI3K/Akt pathway: Promotes cell survival and metabolic regulation
  • JAK/STAT pathway: Mediates responses to various cytokines and growth factors

Step 3: Second Messengers — Signal Amplification

One of the most elegant features of peptide signaling is amplification. A single peptide molecule binding a single receptor can trigger the production of thousands of second messenger molecules inside the cell. This is how tiny amounts of circulating hormone produce powerful physiological effects.

cAMP (Cyclic Adenosine Monophosphate)

The most well-characterized second messenger in peptide signaling. When a Gαs-coupled receptor is activated, the alpha subunit stimulates adenylyl cyclase — an enzyme embedded in the cell membrane — to convert ATP into cAMP.

Since ATP is abundant inside cells and adenylyl cyclase is a fast enzyme, this step produces a rapid burst of cAMP. The cAMP activates protein kinase A (PKA), which phosphorylates a variety of target proteins depending on the cell type. PKA can:

  • Activate enzymes involved in glucose metabolism (relevant to how glucagon raises blood sugar)
  • Modulate gene expression through transcription factor CREB
  • Regulate ion channels
  • Alter cytoskeletal proteins

This pathway is central to how many peptide hormones work. GLP-1 receptor activation (the mechanism behind semaglutide and tirzepatide) increases cAMP in pancreatic beta cells, which stimulates insulin secretion.

Calcium (Ca²⁺) and the IP3/DAG System

When Gαq-coupled receptors are activated, they stimulate phospholipase C (PLC). PLC cleaves a membrane lipid called PIP2 into two molecules:

  • IP3 (inositol trisphosphate): Travels to the endoplasmic reticulum and triggers the release of stored calcium ions into the cytoplasm.
  • DAG (diacylglycerol): Stays in the membrane and activates protein kinase C (PKC).

The sudden rise in intracellular calcium is itself a powerful signal. Calcium ions bind to calmodulin and other calcium-sensing proteins, which then activate downstream enzymes and transcription factors. Muscle contraction, neurotransmitter release, and hormone secretion all depend on calcium signaling.

Oxytocin provides a clear example. When oxytocin binds its GPCR on uterine smooth muscle cells, the Gαq/IP3/calcium cascade triggers muscle contraction — this is the molecular basis of labor contractions.

Cross-Talk Between Pathways

These pathways don't operate in isolation. GPCR and RTK signals frequently converge on shared downstream targets, particularly the ERK/MAPK cascade. This cross-talk allows cells to integrate multiple signals — a peptide hormone arriving via the blood and a growth factor produced locally can both influence the same cellular decision.

The practical consequence: peptide effects are context-dependent. The same peptide can produce different responses in different tissues, depending on which receptors, G proteins, and downstream effectors are expressed there.

Step 4: Cellular Response — The Outcome

All of this signaling machinery exists to change cell behavior. The specific response depends on the peptide, the receptor, the signaling cascade, and the cell type. Common outcomes include:

Hormone secretion — GLP-1 receptor activation causes pancreatic beta cells to secrete insulin. GHRH receptor activation causes pituitary somatotrophs to secrete growth hormone. These are rapid responses, happening within seconds to minutes.

Gene expression changes — Activated transcription factors (like CREB, downstream of cAMP/PKA) enter the nucleus and turn genes on or off. This changes which proteins the cell produces, with effects appearing over hours to days. When BPC-157 or GHK-Cu upregulate growth factor expression, they're working through gene expression changes.

Cell growth and division — Growth factor peptides acting through RTKs can push cells to proliferate. This is important in wound healing (where you want cell growth) and cancer (where you don't).

Cell migration — Some peptides act as chemoattractants, guiding cells toward a wound site or area of tissue damage. TB-500 is thought to work partly by promoting cell migration through its interaction with actin.

Metabolic regulation — Insulin signaling through its RTK causes cells to take up glucose, synthesize glycogen, and build proteins. The entire metabolic machinery of the cell shifts in response.

Appetite and satiety — GLP-1 and related peptides act on brain receptors (particularly in the hypothalamus and brainstem) to reduce appetite and promote feelings of fullness. This is a major mechanism behind the weight loss effects of semaglutide.

Neurotransmission — Neuropeptides like endorphins, selank, and semax modulate neural signaling by binding to receptors on neurons. Their effects — pain relief, anxiolysis, cognitive modulation — emerge from altered patterns of neural activity.

Step 5: Signal Termination — Turning It Off

A signaling system that can't turn itself off would be dangerous. The body uses several mechanisms to terminate peptide signals:

Receptor desensitization — Within seconds to minutes of sustained agonist exposure, GPCRs undergo phosphorylation by G protein-coupled receptor kinases (GRKs). This phosphorylation recruits proteins called arrestins, which physically block the receptor from coupling to G proteins. The receptor goes quiet even though the peptide is still bound.

Receptor internalization — After desensitization, the receptor-peptide complex is pulled inside the cell via endocytosis. This removes the receptor from the cell surface, further reducing the signal. Inside the cell, the receptor may be recycled back to the surface (resensitization) or directed to lysosomes for degradation (downregulation).

Second messenger degradation — Phosphodiesterases break down cAMP back into AMP. Phosphatases remove phosphate groups added by kinases. Calcium pumps restore low intracellular calcium levels. These enzymatic processes reset the cell's internal state.

Peptide degradation — Proteases and peptidases in the blood and tissues break down the peptide itself. Natural GLP-1 has a half-life of about 2 minutes because the enzyme DPP-4 rapidly cleaves it. This is why synthetic analogs like semaglutide are engineered with modifications (Aib substitution, fatty acid chain) that resist enzymatic degradation.

Understanding termination matters for pharmacology. Drug designers manipulate these pathways. DPP-4 inhibitors (a class of diabetes drugs) work by preventing the degradation of natural GLP-1. Long-acting peptide drugs like semaglutide are designed to resist both receptor desensitization and enzymatic degradation.

Mechanisms by Peptide Category

Different categories of peptides work through different specific mechanisms:

GLP-1 Agonists

Semaglutide, tirzepatide, and liraglutide bind the GLP-1 receptor (a Gαs-coupled GPCR) on pancreatic beta cells, increasing cAMP and stimulating insulin secretion in a glucose-dependent manner. In the brain, they activate GLP-1 receptors in the hypothalamus and brainstem to reduce appetite. They also slow gastric emptying through vagal nerve signaling.

Tirzepatide is a dual agonist that also activates the GIP receptor, engaging a second incretin pathway that further modulates insulin secretion and energy metabolism.

Growth Hormone Secretagogues

CJC-1295 mimics GHRH, binding the GHRH receptor (Gαs-coupled) on pituitary somatotroph cells. The resulting cAMP increase stimulates growth hormone synthesis and release. Ipamorelin works through a different mechanism — it binds the ghrelin receptor (GHS-R1a), also Gαs-coupled, on the same cells. When used together, they activate two different receptor pathways on the same target cells, producing a synergistic effect.

Antimicrobial Peptides

LL-37 and other antimicrobial peptides work by a fundamentally different mechanism. Instead of receptor-mediated signaling, they interact directly with bacterial cell membranes. Their amphipathic structure — one side hydrophilic, the other hydrophobic — allows them to insert into lipid bilayers and form pores, disrupting membrane integrity and killing the bacterium. Some AMPs also work by translocating across the membrane and interfering with intracellular processes.

Tissue Repair Peptides

BPC-157 and TB-500 are thought to work through multiple mechanisms simultaneously. BPC-157 appears to modulate nitric oxide synthesis, upregulate growth factor receptors (particularly VEGF-R2), and influence the FAK-paxillin pathway involved in cell migration and wound healing. TB-500 interacts with actin, promoting cell migration and differentiation. Both likely operate through receptor-mediated signaling, though the exact receptors and pathways remain areas of active investigation.

Copper Peptides

GHK-Cu carries a copper ion to target cells, where it influences the expression of hundreds of genes — upregulating genes involved in wound healing and collagen synthesis, and downregulating genes involved in inflammation and tissue destruction. The copper ion itself acts as a cofactor for enzymes like lysyl oxidase (important for collagen cross-linking) and superoxide dismutase (an antioxidant enzyme).

Bioavailability: Getting the Peptide Where It Needs to Go

The most elegant mechanism of action is irrelevant if the peptide never reaches its target. Bioavailability — the fraction of an administered dose that reaches systemic circulation in active form — is the central challenge of peptide pharmacology.

Routes of Administration and Their Bioavailability

RouteTypical BioavailabilitySpeed of OnsetNotes
Intravenous100%ImmediateClinical/hospital setting
Subcutaneous20-100%15-60 minutesMost common for peptide drugs
Intramuscular20-100%15-30 minutesLess common for peptides
IntranasalVariable, 1-30%10-30 minutesUsed for oxytocin, desmopressin
OralUsually <1%30-120 minutesSevere proteolytic degradation
TopicalLow, local effectVariableLimited to skin layers

Why Oral Delivery Is So Hard

The digestive system has evolved specifically to break down peptides and proteins into absorbable amino acids. Three barriers stand in the way:

  1. Gastric acid and pepsin — The stomach (pH 1-2) denatures peptides while pepsin cleaves them at aromatic amino acid residues.
  2. Pancreatic proteases — Trypsin, chymotrypsin, and elastase in the small intestine break peptide bonds at specific sites.
  3. Poor membrane permeability — Even intact peptides struggle to cross the intestinal epithelium because they're too large and too hydrophilic to passively diffuse through cell membranes.

Oral semaglutide (Rybelsus) overcomes these barriers using SNAC, a permeation enhancer that raises local pH, protects the peptide from pepsin, and helps it cross the gastric lining — but even then, bioavailability is only about 1%. The drug works because semaglutide is so potent that 1% is enough.

Strategies for Improving Peptide Bioavailability

Researchers use several approaches:

  • Cyclization: Removing exposed N- and C-termini that are targets for exopeptidases
  • D-amino acid substitution: Protease enzymes can't recognize mirror-image amino acids
  • N-methylation: Blocks endopeptidase access to peptide bonds
  • PEGylation: Attaching PEG chains that shield from proteases and reduce kidney clearance
  • Lipidation: Fatty acid attachment enables albumin binding, extending circulation time
  • Nanoparticle encapsulation: Wrapping peptides in protective carriers

For more on delivery methods, see our reconstitution guide and injection technique guide.

Why Different Peptides Have Different Effects

Given that most peptides work through similar basic mechanisms (receptor binding → signal transduction → cellular response), why are the effects so varied? The answer lies in three factors:

Receptor specificity. Different peptides bind different receptors. GLP-1 binds the GLP-1 receptor, ghrelin mimetics bind the GHS receptor, and oxytocin binds the oxytocin receptor. Each receptor connects to a different signaling pathway and is expressed on different cell types.

Tissue distribution. Even with the same receptor, the response depends on where it's located. GLP-1 receptors on pancreatic beta cells stimulate insulin. GLP-1 receptors in the brain reduce appetite. Same receptor, different tissue, different outcome.

Downstream signaling context. The same second messenger (say, cAMP) can produce completely different effects in different cells because the downstream effectors — the kinases, transcription factors, and target proteins — are different. A rise in cAMP in a heart muscle cell speeds up contraction. The same rise in a pancreatic beta cell triggers insulin release.

This is why you can't predict a peptide's effects just by knowing which receptor it targets. The full picture requires understanding the receptor, the tissue, and the intracellular signaling context.

FAQ

Do peptides enter cells?

Most peptide hormones and neuropeptides do not enter cells. They bind to receptors on the cell surface and trigger intracellular signaling from outside. Exceptions include cell-penetrating peptides (CPPs), which can cross membranes, and some small lipophilic peptides. Antimicrobial peptides like LL-37 also penetrate bacterial membranes, but by a disruptive mechanism rather than receptor signaling.

What's a second messenger and why does it matter?

A second messenger is a small molecule inside the cell that amplifies and relays signals from cell-surface receptors. The "first messenger" is the peptide itself (the extracellular signal). Second messengers — cAMP, calcium, IP3, DAG — are the intracellular signals. They matter because they enable amplification: one peptide binding event can trigger the production of thousands of second messenger molecules.

How fast do peptides work?

It depends on the mechanism. Peptide effects mediated by ion channels or pre-formed enzymes can happen in seconds (neurotransmitter release, muscle contraction). Effects requiring new protein synthesis through gene expression changes take hours to days. The clinical time course also depends on peptide half-life and dosing — semaglutide's once-weekly dosing, for instance, produces gradual, sustained effects.

Why do some peptides need to be injected?

Because the digestive system breaks them down. Your stomach acid and intestinal enzymes are designed to hydrolyze peptide bonds in dietary protein — they make no distinction between food protein and therapeutic peptides. Subcutaneous injection bypasses the gut entirely, delivering the peptide directly into tissue near blood vessels.

Can two peptides work through the same receptor?

Yes. Many receptors have multiple natural ligands. The GLP-1 receptor, for example, binds natural GLP-1 and synthetic agonists like semaglutide, liraglutide, and exenatide. These all activate the same receptor but may differ in binding affinity, activation kinetics, and downstream signaling patterns — which is partly why they have different clinical profiles.

What determines how long a peptide's effect lasts?

Three main factors: (1) the peptide's half-life (how quickly it's degraded), (2) receptor desensitization and internalization (how quickly the cell shuts down the signal), and (3) the persistence of downstream effects (gene expression changes last longer than transient enzyme activation). Drug designers manipulate all three — extending half-life through modifications, designing molecules that resist receptor desensitization, and targeting pathways with lasting effects.

The Bottom Line

Peptides work through a logical, multi-step process: bind a receptor, trigger a signaling cascade, amplify the signal through second messengers, and produce a specific cellular response. The elegance of this system lies in its specificity and its amplification — a tiny amount of peptide can produce a powerful, targeted effect.

Understanding these mechanisms gives you a framework for evaluating peptide claims. When someone says a peptide "boosts growth hormone," you can ask: through which receptor? Via what signaling pathway? In which tissues? When a skincare brand claims a peptide "stimulates collagen," you can consider: does it actually reach the cells that make collagen? Does it bind a known receptor on those cells?

The science of peptide signaling is well-established, backed by decades of research and underpinning a pharmaceutical market projected to exceed $100 billion by 2033. What's still evolving is our understanding of specific peptides' mechanisms — particularly for newer and less-studied compounds.

For the foundational chemistry, see our guide to amino acids and peptide bonds. For the full vocabulary, check the peptide glossary. And for practical information on specific peptides, explore our individual peptide profiles.

References

  1. Wang L, et al. "Therapeutic peptides: current applications and future directions." Signal Transduction and Targeted Therapy. 2022;7:48. https://www.nature.com/articles/s41392-022-00904-4
  2. Hilger D, et al. "Structure and dynamics of GPCR signaling complexes." Nature Structural & Molecular Biology. 2018;25:4-12. https://pubmed.ncbi.nlm.nih.gov/29323277/
  3. National Center for Biotechnology Information. "Biochemistry, G Protein Coupled Receptors." StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK518966/
  4. Newton AC, et al. "Second messengers." Cold Spring Harbor Perspectives in Biology. 2016;8(8):a005926. https://cshperspectives.cshlp.org/content/8/8/a005926.full
  5. Wacker D, et al. "G protein-coupled receptor-G protein interactions." Current Opinion in Structural Biology. 2017;45:59-68. https://pubmed.ncbi.nlm.nih.gov/28267651/
  6. Davenport AP, et al. "Advances in therapeutic peptides targeting G protein-coupled receptors." Nature Reviews Drug Discovery. 2020;19:389-413. https://pubmed.ncbi.nlm.nih.gov/32494019/
  7. Hupe-Sodmann K, et al. "Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide." Regulatory Peptides. 1995;58(3):149-156. https://pubmed.ncbi.nlm.nih.gov/8577927/
  8. Gurevich VV, Gurevich EV. "GPCR signaling regulation: the role of GRKs and arrestins." Frontiers in Pharmacology. 2019;10:125. https://pubmed.ncbi.nlm.nih.gov/30837883/
  9. Latek D, et al. "G protein-coupled receptors — recent advances." Acta Biochimica Polonica. 2012;59(4):515-529. https://pubmed.ncbi.nlm.nih.gov/23251911/
  10. Bachem. "Bioavailability of peptides." https://www.bachem.com/articles/peptides/bioavailability-of-peptides/
  11. Drucker DJ, Nauck MA. "The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes." The Lancet. 2006;368(9548):1696-1705. https://pubmed.ncbi.nlm.nih.gov/17098089/
  12. Brogden KA. "Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?" Nature Reviews Microbiology. 2005;3(3):238-250. https://pubmed.ncbi.nlm.nih.gov/15703760/